2025 · 2nd Quarter (Apr 1 - June 30)
Filed by OTSUKA AMERICA PHARMACEUTICAL, INC..
Open official filingSource-reported fields
Expense method: A
Literal source text
Issues related to tax reform efforts, issues stemming from the Tax Cuts and Jobs Act of 2017, and other corporate tax issues, including provisions in H.R. 1, the One Big Beautiful Bill Act, relating to corporate tax rates and international business taxes.
Literal federal measure citations: H.R. 1
Health care policies relating to mental health and PTSD, including authorizations and appropriations for the Department of Veterans Affairs related to mental health and PTSD.
Issues related to tariffs on pharmaceuticals and pharmaceutical supply chain.
Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low-income subsidy beneficiaries.
Issues relating to agitation in Alzheimer's disease, early detection of PTSD, mental health parity and coordinated care, mental health equity. PBM reform. Issues related to rare nephrology, 340B reform, psychedelics treatments for PTSD and mental health. The BIOSECURE Act. Ensuring Pathways to Innovative Cures (EPIC) Act (S.832/HR 1492). Issues related to drug pricing, foreign reference pricing, biomedical research, and pharmaceutical supply chain. Provisions in H.R. 1, the One Big Beautiful Bill Act relating to pharmaceuticals.
Provisions related to pharmaceuticals in Continuing Appropriations and Other Matters Act, 2025, and provisions in H.R. 1, the One Big Beautiful Bill Act concerning appropriations for the Department of Health & Human Services and the Department of Veterans Affairs related to mental health and PTSD.
Literal federal measure citations: H.R. 1
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.
